Evotec (EVO) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership.

Is BPMC or EVO more profitable?

Evotec has a net margin of 0.00% compared to Blueprint Medicines' net margin of -29.48%. Evotec's return on equity of 0.00% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-29.48%	-112.30%	-26.87%
Evotec	N/A	N/A	N/A

Does the MarketBeat Community favor BPMC or EVO?

Blueprint Medicines received 527 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 67.98% of users gave Blueprint Medicines an outperform vote while only 54.55% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 533 67.98%	Underperform Votes 251 32.02%
Evotec	Outperform Votes 6 54.55%	Underperform Votes 5 45.45%

Do institutionals and insiders have more ownership in BPMC or EVO?

5.8% of Evotec shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more volatility and risk, BPMC or EVO?

Blueprint Medicines has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Does the media favor BPMC or EVO?

In the previous week, Evotec had 2 more articles in the media than Blueprint Medicines. MarketBeat recorded 22 mentions for Evotec and 20 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.69 beat Evotec's score of 0.32 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts recommend BPMC or EVO?

Blueprint Medicines currently has a consensus price target of $122.11, indicating a potential upside of 37.68%. Evotec has a consensus price target of $5.93, indicating a potential upside of 9.07%. Given Blueprint Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Blueprint Medicines is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.71
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Which has better earnings and valuation, BPMC or EVO?

Evotec has higher revenue and earnings than Blueprint Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$249.38M	22.59	-$506.98M	-$2.11	-42.03
Evotec	$845.74M	2.28	-$90.82M	N/A	N/A

Summary

Blueprint Medicines beats Evotec on 9 of the 17 factors compared between the two stocks.